Abcentra Working to Fight Cardiovascular Disease
Wednesday October 2, 2019
In a 2017 study by the Institute for Health Metrics and Evaluation (IHME), cardiovascular disease was cited as the major cause of mortality among adults aged 35-70 years, and accounted for one-third of deaths throughout the world.
Abcentra is committed to bringing the latest breakthroughs in inflammation therapy to patients with serious inflammatory diseases, which include certain types of cardiovascular diseases and diseases for which no treatments currently exist. Often, oxidized low density lipoprotein (oxLDL) can be implicated in common, chronic conditions caused by inflammation such as cardiovascular disease, psoriasis and rheumatoid disease. Indeed, traditional inflammatory diseases have increased the incidence and progression of cardiovascular diseases, such as atherosclerosis (“accelerated atherosclerosis”).
Atherosclerosis occurs when substances such as fats, cholesterol, and immune cells build up on a patient’s artery walls, restricting blood flow to vital organs and tissues. It often goes undiscovered until a serious event occurs, such as a heart attack or stroke. Many traditional treatments for accelerated atherosclerosis are limited in reach and may have severe side effects like infections, cancer and death. However, with specific targeting of oxLDL, we can treat underlying inflammation associated with the disease without serious risks associated with traditional medicines.
Plaque psoriasis is a chronic inflammatory skin disease associated with serious conditions such as cancer, diabetes and heart disease. Traditional therapies can have serious side effects and potentially increase risk of infections and cancer. Targeted treatment of oxLDL may lead to an effective, minimal side effect therapy for such patients.
Abcentra’s lead candidate, orticumab, is the first and only fully-human monoclonal antibody of its kind targeting oxLDL, which we are developing to treat inflammation, manifest in diseases like psoriasis and the associated cardiovascular disease, namely accelerated atherosclerosis. Through targeting oxLDL, Abcentra is working to find a solution for patients suffering from these types of inflammatory diseases, including psoriasis, rheumatoid disease, and cardiovascular disease, giving patients better treatment options and a fuller life.
Abcentra is creating novel solutions to provide better options for patients and treat diseases for which no current treatment options exist. For more information about our lead candidate, read more about our science, or view our pipeline to learn more about the other treatment options currently in development.